Story perspectives

Pfizer Acquires Metsera Amid Revenue Declines, Targets Weight Loss Market

12/1/2025

30 6

Summary

Story summary

Pfizer reports a 55% drop in Paxlovid revenue and a 20% decline in Comirnaty revenue in Q3 2025.
To counteract losses, Pfizer acquired biotech start-up Metsera for $10 billion to enter the $133 billion weight loss drug market.
Metsera's obesity drugs could generate significant revenue.
Pfizer's collaboration with AI technology has improved drug development efficiency, potentially saving $7.7 billion.
Pfizer's dividend yield remains attractive at 6.9% for income-focused investors.

1 of 1

Story summary

Pfizer reports a 55% drop in Paxlovid revenue and a 20% decline in Comirnaty revenue in Q3 2025.
To counteract losses, Pfizer acquired biotech start-up Metsera for $10 billion to enter the $133 billion weight loss drug market.
Metsera's obesity drugs could generate significant revenue.
Pfizer's collaboration with AI technology has improved drug development efficiency, potentially saving $7.7 billion.
Pfizer's dividend yield remains attractive at 6.9% for income-focused investors.